SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.

Pharmaceutical

SciClone Pharmaceuticals Inc

宏 赵

David Wilgus

Peter Shao

Li Mao

岩松（Phil） 常

Cecile Pan

Bokang Zhou

The Leadership Team at SciClone Pharmaceuticals Inc. is responsible for setting the strategic direction and operational priorities of the company. Comprising key executives from various disciplines—medical, technical operations, marketing, finance, and oncology management—they collaborate to drive innovation, optimize product offerings, and ensure compliance with regulatory standards in both the Chinese market and internationally. Their collective expertise guides the development of therapies and strengthens SciClone's position within the global pharmaceutical landscape.

Leadership Team

Medical Affairs and Regulatory Compliance

Business Development and Strategy

Leadership Team

About

Team members

Other teams at SciClone Pharmaceuticals Inc

Medical Affairs and Regulatory Compliance

Business Development and Strategy